<DOC>
	<DOCNO>NCT00797069</DOCNO>
	<brief_summary>Compare glycemic insulinemic response standard nutritional product two diabetes-specific nutritional product patient type 2 diabetes .</brief_summary>
	<brief_title>Comparison Nutritional Products People With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Subject state he/she type 2 diabetes ( evidence use oral hypoglycemic medication least two month ) . 2 . Subject 18 75 year age , inclusive . 3 . Subject male nonpregnant , nonlactating female , least 6 week postpartum prior screen visit . 4 . If female childbearing potential , practice method birth control . 5 . Subject 's BMI &gt; 18.5 kg/m2 &lt; 35 kg/m2 . 6 . If chronic medication antihypertensive , lipidlowering , thyroid medication hormone therapy , subject constant dosage least two month prior screen visit . 1 . Subject use exogenous insulin glucose control . 2 . Subject state he/she type 1 diabetes . 3 . Subject state he/she history diabetic ketoacidosis . 4 . Subject take alphaglucosidase inhibitor . 5 . Subject state he/she current infection ; inpatient surgery , corticosteroid treatment last 3 month antibiotic last 3 week prior screen visit . 6 . Subject state he/she active malignancy ( exclude follow dermal malignancy : basal cell carcinoma , squamous cell carcinoma , carcinoma insitu cervix ) . 7 . Subject state he/she significant cardiovascular event â‰¤ six month prior screen visit ; state history congestive heart failure . 8 . Subject state he/she end stage organ failure status post organ transplant . 9 . Subject state he/she history renal disease . 10 . Subject state he/she current hepatic disease . 11 . Subject state he/she history severe gastroparesis . 12 . Subject state he/she chronic , contagious , infectious disease , active tuberculosis , Hepatitis B C , HIV . 13 . Subject taken/is currently take herbal , dietary supplement , medication , oral hypoglycemic medication , past four week prior screen visit could profoundly affect blood glucose . 14 . Subject state he/she clot bleeding disorder . 15 . Subject know allergic intolerant ingredient find study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>